Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GLOBUS MEDICAL INCGMED · Entity 3496 | Director | September 15, 2026 | September 16, 2026 |
| Lyra Therapeutics, Inc.LYRA · Entity 46837 | Director | May 14, 2025 | May 16, 2025 |
| TransMedics Group, Inc.TMDX · Entity 4261 | Director | August 17, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GLOBUS MEDICAL INC
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 15,000 · Balance 15,000 Row 2 · 2026-09-15 · Exercise / conversion · Acquired 15,000 · Balance 30,000 Row 3 · 2026-09-15 · Sale · Disposed 30,000 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.33 to $74.96, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. |
| Stock Option (Right to Buy Class A Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $53.75 · Expires 2034-01-26 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-15 · Exercise / conversion · Disposed 15,000 · Balance 0 F2: These options were granted on January 26, 2024 and are fully vested. |
| Stock Option (Right to Buy Class A Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $63.68 · Expires 2032-01-27 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-15 · Exercise / conversion · Disposed 15,000 · Balance 0 F3: These options were granted on January 27, 2022 and are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.33 to $74.96, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2: These options were granted on January 26, 2024 and are fully vested.
F3: These options were granted on January 27, 2022 and are fully vested.
Lyra Therapeutics, Inc.
Report date May 14, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 32,000 |
Reported balance
After 2025-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-14 · Grant · Acquired 32,000 · Balance 32,000 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.
TransMedics Group, Inc.
Report date August 17, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Tobin 2024 Family Trust | 0 |
Reported balance
After 2026-08-17 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-17 · Gift · Disposed 18,000 · Balance 0 |
| Common StockSEC Table I · non-derivative | Direct | 6,981 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,981 |
| Common StockSEC Table I · non-derivative | IndirectBy the James R. Tobin 2012 Trust | 155,146 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 155,146 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Corindus Vascular Robotics, Inc.
Report date October 29, 2019 · Filed October 31, 2019
Section 16 reporting ended · disclosed 2019-10-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 1
1 source rowRow 1 · 2019-10-29 · Disposition to issuer · Disposed 106,112 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: These shares represent 85,375 shares of the Issuer's common stock and 20,737 restricted stock units ("RSUs"). F3: At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, (i) each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $4.28 in cash, without interest and less any applicable withholding taxes, and (ii) each outstanding RSU converted into the right to receive a cash payment equal to the product of (a) $4.28 and (b) the number of shares of the Issuer's common stock underlying the RSU as of the Effective Time, without interest and net of any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
F2: These shares represent 85,375 shares of the Issuer's common stock and 20,737 restricted stock units ("RSUs").
F3: At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, (i) each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $4.28 in cash, without interest and less any applicable withholding taxes, and (ii) each outstanding RSU converted into the right to receive a cash payment equal to the product of (a) $4.28 and (b) the number of shares of the Issuer's common stock underlying the RSU as of the Effective Time, without interest and net of any applicable withholding taxes.
Oxford Immunotec Global PLC
Report date March 08, 2021 · Filed March 12, 2021
Section 16 reporting ended · disclosed 2021-03-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 1
1 source rowRow 1 · 2021-03-08 · Disposition to issuer · Disposed 4,081 · Balance 0 F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2026-06-28 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.46 · Expires 2027-06-06 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.49 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.44 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.02 · Expires 2024-12-01 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-08 · Disposition to issuer · Disposed 14,914 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.02 · Expires 2024-12-01 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2025-06-09 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.96 · Expires 2030-06-24 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-03-08 · Disposition to issuer · Disposed 9,494 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price.
F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 16, 2026 20:35 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | Exercise / conversionStock Option (Right to Buy Class A Common Stock) · Derivative | 15,000 | $0.00 Strike: $63.68 | $0.00 |
DisclosureSEC source: 0001193125-26-393147 · ownership.xml · derivative · entry 5 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 15,000 shares Expires 2032-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options were granted on January 27, 2022 and are fully vested. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:35 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | Exercise / conversionStock Option (Right to Buy Class A Common Stock) · Derivative | 15,000 | $0.00 Strike: $53.75 | $0.00 |
DisclosureSEC source: 0001193125-26-393147 · ownership.xml · derivative · entry 4 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 15,000 shares Expires 2034-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options were granted on January 26, 2024 and are fully vested. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:35 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | SaleClass A Common Stock | 30,000 | $74.58 | $2,237,502.00 |
DisclosureSEC source: 0001193125-26-393147 · ownership.xml · nonDerivative · entry 3 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.33 to $74.96, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:35 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | Exercise / conversionClass A Common Stock | 15,000 | $63.68 | $955,200.00 |
DisclosureSEC source: 0001193125-26-393147 · ownership.xml · nonDerivative · entry 2 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:35 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | Exercise / conversionClass A Common Stock | 15,000 | $53.75 | $806,250.00 |
DisclosureSEC source: 0001193125-26-393147 · ownership.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 20:45 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GiftCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-354202 · ownership.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Tobin 2024 Family Trust Disclosed balance after: 0 Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:15 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 2,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-236906 · ownership.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,981 F1 · shares: Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 21:53 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | GrantStock Option (Right to Buy Class A Common Stock) · Derivative | 15,000 | $0.00 Strike: $94.15 | $0.00 |
DisclosureSEC source: 0001193125-26-021205 · ownership.xml · derivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2036-01-21 F1 · derivative.exercise_date: These options were granted on January 21, 2026, and will vest on January 1, 2027. Read SEC document |
| May 22, 2025 Filed May 23, 2025 22:47 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 2,134 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-077221 · ownership.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,059 F1 · shares: Consists of 2,134 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:30 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantRestricted Stock Units · Derivative | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073609 · ownership.xml · derivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan. Read SEC document |
| January 23, 2025 Filed Mar 28, 2025 22:41 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | GrantStock Option (Right to Buy Class A Common Stock) · Derivative | 15,000 | $0.00 Strike: $92.42 | $0.00 |
DisclosureSEC source: 0000950170-25-047024 · ownership.xml · derivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2035-01-23 F1 · derivative.exercise_date: These options were granted on January 23, 2025, and will vest on January 1, 2026. Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 23:27 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GiftCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-107493 · ownership.xml · nonDerivative · entry 2 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Tobin 2024 Family Trust Disclosed balance after: 18,000 Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 23:27 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GiftCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-107493 · ownership.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 155,146 Read SEC document |
| August 08, 2024 Filed Aug 9, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 7,336 | $159.96 | $1,173,466.56 |
DisclosureSEC source: 0000950170-24-094806 · ownership.xml · nonDerivative · entry 2 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 173,146 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $159.77 to $160.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 08, 2024 Filed Aug 9, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 12,664 | $158.96 | $2,013,069.44 |
DisclosureSEC source: 0000950170-24-094806 · ownership.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 180,482 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $158.75 to $159.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:10 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0000950170-24-073649 · ownership.xml · derivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 1,154 | $0.00 Strike: $137.53 | $0.00 |
DisclosureSEC source: 0000950170-24-065398 · ownership.xml · derivative · entry 3 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,154 Underlying: Common Stock · 1,154 shares Expires 2034-05-23 F2 · derivative.exercise_date: The option vests in full on the earlier of May 23, 2025 or the date of the 2025 annual meeting of the stockholders of the Issuer, subject to continued service. Read SEC document |
| May 23, 2024 Filed May 28, 2024 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 732 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-065398 · ownership.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,925 F1 · shares: Consists of 732 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 6,895 | $125.26 | $863,667.70 |
DisclosureSEC source: 0000950170-24-054600 · ownership.xml · nonDerivative · entry 2 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 193,146 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 21, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $125.00 to $125.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 5,130 | $124.76 | $640,018.80 |
DisclosureSEC source: 0000950170-24-054600 · ownership.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 200,041 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 21, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $124.75 to $124.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:32 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,000 | $110.00 | $220,000.00 |
DisclosureSEC source: 0000950170-24-052972 · ownership.xml · nonDerivative · entry 4 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 205,171 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 21, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:32 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 100 | $108.47 | $10,847.00 |
DisclosureSEC source: 0000950170-24-052972 · ownership.xml · nonDerivative · entry 3 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 207,171 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 21, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:32 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,704 | $106.89 | $182,140.56 |
DisclosureSEC source: 0000950170-24-052972 · ownership.xml · nonDerivative · entry 2 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 207,271 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 21, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.58 to $107.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:32 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 11,236 | $105.70 | $1,187,645.20 |
DisclosureSEC source: 0000950170-24-052972 · ownership.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 208,975 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 21, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.50 to $106.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:16 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 300 | $85.48 | $25,644.00 |
DisclosureSEC source: 0000950170-24-026472 · ownership.xml · nonDerivative · entry 5 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 220,211 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 21, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $85.39 to $85.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:16 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,900 | $84.74 | $245,746.00 |
DisclosureSEC source: 0000950170-24-026472 · ownership.xml · nonDerivative · entry 4 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 220,511 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 21, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $84.28 to $85.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:16 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 5,746 | $83.63 | $480,537.98 |
DisclosureSEC source: 0000950170-24-026472 · ownership.xml · nonDerivative · entry 3 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 223,411 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 21, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $83.26 to $84.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:16 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 4,234 | $82.84 | $350,744.56 |
DisclosureSEC source: 0000950170-24-026472 · ownership.xml · nonDerivative · entry 2 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 229,157 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 21, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $82.25 to $83.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:16 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 200 | $81.41 | $16,282.00 |
DisclosureSEC source: 0000950170-24-026472 · ownership.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 233,391 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on November 21, 2023. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:53 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | GrantStock Option (Right to Buy Class A Common Stock) · Derivative | 15,000 | $0.00 Strike: $53.75 | $0.00 |
DisclosureSEC source: 0000950170-24-008924 · ownership.xml · derivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2034-01-26 F1 · derivative.exercise_date: These options were granted on January 26, 2024, and will vest on January 1, 2025. Read SEC document |
| November 28, 2023 Filed Nov 29, 2023 21:38 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 10,000 | $70.14 | $701,400.00 |
DisclosureSEC source: 0000950170-23-066771 · ownership.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 233,591 Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 01:53 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0000950170-23-031873 · ownership.xml · derivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-29 F1 · derivative.exercise_date: This option vests and becomes exercisable on June 30, 2024, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:32 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 1,916 | $0.00 Strike: $71.33 | $0.00 |
DisclosureSEC source: 0000950170-23-024887 · ownership.xml · derivative · entry 3 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,916 Underlying: Common Stock · 1,916 shares Expires 2023-05-25 F2 · derivative.exercise_date: The option vests in full on the earlier of May 25, 2024 or the date of the 2024 annual meeting of the stockholders of the Issuer, subject to continued service. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:32 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 1,193 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-024887 · ownership.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,193 F1 · shares: Includes 1,193 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 01:00 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 10,000 | $75.13 | $751,300.00 |
DisclosureSEC source: 0000899243-23-006281 · doc4.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 243,591 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $75.00 to $75.59, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 26, 2023 Filed Feb 27, 2023 22:01 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | GrantStock Option (Right to Buy Class A Common Stock) · Derivative | 15,000 | $0.00 Strike: $75.18 | $0.00 |
DisclosureSEC source: 0001209191-23-013249 · doc4.xml · derivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2033-01-26 F1 · derivative.exercise_date: These options were granted on January 26, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 00:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 48,515 | $39.98 | $1,939,629.70 |
DisclosureSEC source: 0000899243-22-027253 · doc4.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 253,591 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $39.90 to $40.10, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 22:17 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 48,515 | $35.00 | $1,698,025.00 |
DisclosureSEC source: 0000899243-22-025482 · doc4.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 302,106 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $34.90 to $35.12, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2022 Filed Jun 6, 2022 20:28 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 13,500 | $0.00 Strike: $28.12 | $0.00 |
DisclosureSEC source: 0000899243-22-021194 · doc4.xml · derivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2032-06-01 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant, June 1, 2023, or the date of the following annual meeting of shareholders of the Company. Read SEC document |
| May 04, 2022 Filed May 6, 2022 20:05 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 48,516 | $29.94 | $1,452,569.04 |
DisclosureSEC source: 0000899243-22-017085 · doc4.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the James R. Tobin 2012 Trust Disclosed balance after: 350,621 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $29.90 to $30.07, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:45 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | Exercise / conversionStock Option (Right to Buy Class A Common Stock) · Derivative | 3,542 | $0.00 Strike: $53.27 | $0.00 |
DisclosureSEC source: 0001209191-22-019620 · doc4.xml · derivative · entry 5 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,458 Underlying: Class A Common Stock · 3,542 shares Expires 2030-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options were granted on January 22, 2020 and are fully vested. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:45 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | Exercise / conversionStock Option (Right to Buy Class A Common Stock) · Derivative | 5,308 | $0.00 Strike: $43.58 | $0.00 |
DisclosureSEC source: 0001209191-22-019620 · doc4.xml · derivative · entry 4 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,208 Underlying: Class A Common Stock · 5,308 shares Expires 2029-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options were granted on January 22, 2019 and are fully vested. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:45 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | SaleClass A Common Stock | 8,850 | $65.47 | $579,418.35 |
DisclosureSEC source: 0001209191-22-019620 · doc4.xml · nonDerivative · entry 3 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.09 to $66.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:45 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | Exercise / conversionClass A Common Stock | 3,542 | $53.27 | $188,682.34 |
DisclosureSEC source: 0001209191-22-019620 · doc4.xml · nonDerivative · entry 2 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:45 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | Exercise / conversionClass A Common Stock | 5,308 | $43.58 | $231,322.64 |
DisclosureSEC source: 0001209191-22-019620 · doc4.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 01:07 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | Exercise / conversionStock Option (Right to Buy Class A Common Stock) · Derivative | 10,000 | $0.00 Strike: $43.58 | $0.00 |
DisclosureSEC source: 0001209191-22-018065 · doc4.xml · derivative · entry 6 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,516 Underlying: Class A Common Stock · 10,000 shares Expires 2029-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options were granted on January 22, 2019 and are fully vested. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 01:07 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | SaleClass A Common Stock | 10,000 | $70.04 | $700,398.00 |
DisclosureSEC source: 0001209191-22-018065 · doc4.xml · nonDerivative · entry 4 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.135, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 01:07 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | Exercise / conversionClass A Common Stock | 10,000 | $43.58 | $435,800.00 |
DisclosureSEC source: 0001209191-22-018065 · doc4.xml · nonDerivative · entry 3 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 01:07 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | Exercise / conversionStock Option (Right to Buy Class A Common Stock) · Derivative | 4,484 | $0.00 Strike: $43.58 | $0.00 |
DisclosureSEC source: 0001209191-22-018065 · doc4.xml · derivative · entry 5 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,516 Underlying: Class A Common Stock · 4,484 shares Expires 2029-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options were granted on January 22, 2019 and are fully vested. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 01:07 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | SaleClass A Common Stock | 4,484 | $72.00 | $322,848.00 |
DisclosureSEC source: 0001209191-22-018065 · doc4.xml · nonDerivative · entry 2 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.